“While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the urethra and other critical structures," says Ryan Rhodes.
"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive disease," says Andrea Necchi, MD.
"We remain on track for the opening of phase 2 in the next few months. We also expect to see the full phase 1 results presented at a scientific meeting in 2025," says David E. Gauden, DPhil.
Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.
The WATER IV PCa will assess Aquablation vs radical prostatectomy in patients with grade group 1 to 3 localized prostate cancer.
Illuccix is now indicated for use in the selection of patients with mCRPC for PSMA-targeted radionuclide therapy.
“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.
The overall report rate per unit sold of the PEG hydrogel spacers was 0.40%.
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT," the authors wrote.
At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.
The 3-year biochemical progression-free survival was 61%, and the 3-year radiographic progression-free survival was 67%.
The estimated 10-year cumulative incidence of PCSM was 1.2% for those who did not experience biochemical recurrence within 5 years of radiotherapy vs 29.0% among those who did.
"We think that radiation therapy is one of the best treatment options available for kidney cancer," says Nicholas Zaorsky, MD, MS.
The phase 3 ENLIGHTED trial has reached the 50% patient enrollment threshold.
“Our findings give patients and doctors valuable insights into what to expect after ADT treatment, helping them make informed decisions about managing side effects and improving long-term outcomes," says Amar U. Kishan, MD.
"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.
With this integration, imaging data from the DeepHealth software can be readily imported to the Trinity 3D Ultrasound Platform for prostate fusion biopsy.
The recommended phase 2 dose was determined to be rogaratinib at 600 mg in combination with atezolizumab at 1200 mg.
Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW.
According to the authors, these findings from the VOLGA trial suggest that ctDNA may be a potential biomarker to predict therapeutic benefit in patients with MIBC.
"Interestingly, the findings from this study have already translated into an investigator-initiated clinical trial," says John P. Sfakianos, MD.
“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," the authors write.
No patients in the transperineal cohort experienced an infection, compared with 1.6% of patients in the transrectal cohort.
“Our PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools," wrote the authors.
According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.”
At a median follow-up of 9 months, the confirmed objective response rate to disitamab vedotin plus pembrolizumab was 75% in the overall population.
Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.
According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC.
“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD.
